-
Rasagiline, sold
under the
brand name
Azilect among others, is a
medication which is used in the
treatment of Parkinson's disease. It is used as a monotherapy...
- imipramine, desipramine),
monoamine oxidase inhibitors (MAOIs) (e.g.,
rasagiline),
serotonin antagonists and
reuptake inhibitors (SARIs) (e.g., nefazodone)...
- MAO-B
inhibitor and
antiparkinsonian agent rasagiline ((R)-N-propargyl-1-aminoindane). In
contrast to
rasagiline, it
lacks significant monoamine oxidase...
-
pharmacologically active and is an
active metabolite of the
antiparkinsonian agent rasagiline.
Through its (R)-enantiomer (R)-1-aminoindane, 1-aminoindane has pharmacological...
-
racemic rasagiline or as N-propargyl-1-aminoindane) is a
monoamine oxidase inhibitor (MAOI) that was
never marketed. It is the
racemic form of
rasagiline and...
- disease.
There is
evidence that
selegiline may be more
effective than
rasagiline in the
treatment of Parkinson's disease. This may be due to pharmacological...
- is less
selective for MAO-B
inhibition than AGN-1135 (racemic
rasagiline) or
rasagiline. In
addition to its MAOI activity, SU-11739 has been reported...
- Parkinson's disease. It was
developed from
structural modification of
rasagiline. The drug acts as a
reversible acetylcholinesterase and butyrylcholinesterase...
- B
propargyl amine inhibitor rasagiline (N-propargyl-1-R-aminoindan, Azilect((R))). The oral
bioavailability of
rasagiline is 35%, it
reaches T(max) after...
- treatment, e.g. in
multiple sclerosis Livedo reticularis ****ociated with
rasagiline Methylphenidate and dextroamphetamine-induced
peripheral vasculopathy...
